SNTA Share Price

Open 0.28 Change Price %
High 0.40 1 Day 0.07 25.93
Low 0.27 1 Week 0.00 0.00
Close 0.34 1 Month 0.00 0.00
Volume 9322967 1 Year -0.07 -17.07
52 Week High 0.45
52 Week Low 0.15
SNTA Important Levels
Resistance 2 0.46
Resistance 1 0.41
Pivot 0.34
Support 1 0.27
Support 2 0.22
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.70 0.20%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
RITT 0.06 -45.45%
DVOX 0.05 -44.44%
More..

Synta Pharmaceuticals Corp. (NASDAQ: SNTA)

SNTA Technical Analysis 2
As on 22nd Jul 2016 SNTA Share Price closed @ 0.34 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.65 & Buy for SHORT-TERM with Stoploss of 0.33 we also expect STOCK to react on Following IMPORTANT LEVELS.
SNTA Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
SNTA Other Details
Segment EQ
Market Capital 451457792.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.syntapharma.com
SNTA Address
SNTA
45 Hartwell Avenue
Lexington, MA 02421
United States
Phone: 781-274-8200
Fax: 781-274-8228
Interactive Technical Analysis Chart Synta Pharmaceuticals Corp. ( SNTA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Synta Pharmaceuticals Corp.
SNTA Business Profile
Synta Pharmaceuticals Corp. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing small molecule drugs to severe the medical conditions of the patients with cancer and inflammatory diseases. As of December 31, 2011, it had two drug candidates in clinical trials for treating multiple types of cancer and several drug candidates in the preclinical-stage of development. Its drug candidates are discovered and developed internally, using its chemical compound library and integrated discovery engine. During the year ended December 31, 2011, it initiated a Phase 2b/3 clinical trial (GALAXY) of ganetespib in combination with docetaxel in non-small cell lung cancer (NSCLC). As of December 31, 2011, it had two clinical-stage programs and one preclinical-stage program in oncology. In 2011, in addition to focusing on ganetespib program, the Company also focused on its elesclomol and calcium release activated calcium modulator (CRAC) programs.